180 Life Sciences Corporate Media Kit

11 Competitive Advantages • Expert Investigators ─ Established reputation in conducting clinical trials across academic and clinical networks (1) ─ Well practiced in publishing trials in peer reviewed clinical journals • Cost Effective ─ No payment for trial patients required in the UK/EU ─ Staff costs can be covered by academic grants (Wellcome Trust, NIHR) • Shorter Timeline for Recruitment and Execution ─ Access to large registries of patients/diseases ─ Regulatory expertise in writing protocols, seeking approvals, conducting trials. Cost Effective, Time Efficient, Academic Led Clinical Trials Performed in UK (1) https://www.ndorms.ox.ac.uk/octru Developing the Only Treatment for Early Stage Fibrosis • Studies in DD lead the way for novel approach to develop clinical programs in other fibrotic diseases: ─ Tissues and cells from most fibrotic diseases not readily accessible as diagnosed late ─ Competitors use animals or late stage cells in culture, neither reflect human disease ─ Our use of human tissue makes preclinical discovery more relevant and accurate, mitigating risk for clinical stage • Currently no competition for targeting and preventing early stage fibrosis • Non-surgical, easy to administer • Short term treatment, intended to halt disease progression Novel Use Of Human Disease Tissue To Identify New Targets In Fibrosis 180 Life Sciences Corp. www.180lifesciences.com Q4 2020